Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 7;13(6):843.
doi: 10.3390/pharmaceutics13060843.

Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects

Affiliations
Review

Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects

Noha Attia et al. Pharmaceutics. .

Abstract

The cell-based approach in gene therapy arises as a promising strategy to provide safe, targeted, and efficient gene delivery. Owing to their unique features, as homing and tumor-tropism, mesenchymal stem cells (MSCs) have recently been introduced as an encouraging vehicle in gene therapy. Nevertheless, non-viral transfer of nucleic acids into MSCs remains limited due to various factors related to the main stakeholders of the process (e.g., nucleic acids, carriers, or cells). In this review, we have summarized the main types of nucleic acids used to transfect MSCs, the pros and cons, and applications of each. Then, we have emphasized on the most efficient lipid-based carriers for nucleic acids to MSCs, their main features, and some of their applications. While a myriad of studies have demonstrated the therapeutic potential for engineered MSCs therapy in various illnesses, optimization for clinical use is an ongoing challenge. On the way of improvement, genetically modified MSCs have been combined with various novel techniques and tools (e.g., exosomes, spheroids, 3D-Bioprinting, etc.,) aiming for more efficient and safe applications in biomedicine.

Keywords: 3D-bioprinting; COVID-19; cell therapy; gene therapy; mesenchymal stem cell; niosome; non-viral gene delivery; transfection.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Viral and non-viral carriers of nucleic acids. NLC: nanostructured lipid carrier, SLN: solid lipid nanoparticles, CP: cell penetrating, NPs: nanoparticles.
Figure 2
Figure 2
Schematic structure of liposomes showing different compositions. [70]. CC BY 4.0 license.
Figure 3
Figure 3
Some innovative approaches for improving gene delivery by MSCs.
Figure 4
Figure 4
Nioplexes-loaded HA hydrogels for transfection of MSCs [130]. CC BY 4.0 license.
Figure 5
Figure 5
Multi-material bioinks used to bioprint 3D constructs for various biological applications [131].CC BY-NC-ND 4.0.

Similar articles

Cited by

References

    1. Attia N., Mashal M. Mesenchymal Stem Cells: The Past Present and Future. Spinger; New York, NY, USA: 2020. - PubMed
    1. Mehanna R.A., Nabil I., Attia N., Bary A.A., Razek K.A., Ahmed T.A., Elsayed F. The effect of bone marrow-derived mesenchymal stem cells and their conditioned media topically delivered in fibrin glue on chronic wound healing in rats. BioMed Res. Int. 2015;2015 doi: 10.1155/2015/846062. - DOI - PMC - PubMed
    1. Afanasyev B.V., Elstner E.E., Zander A.R. AJ Friedenstein, founder of the mesenchymal stem cell concept. Cell Ther. Transpl. 2009;1:35–38.
    1. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic transplants of bone marrow. Transplant. 1968;6:230–247. doi: 10.1097/00007890-196803000-00009. - DOI - PubMed
    1. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008;8:726–736. doi: 10.1038/nri2395. - DOI - PubMed

LinkOut - more resources